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and informed approach to long term catheterisation
and are eager to support further research into specific
aspects of catheter management. Two short booklets
are available from Bard Limited for patients and those
responsible for their care, and further information will
be gladly given to any doctor heeding Mr Kinder's
call.
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Alcohol and violence
Mr M CAREW-MCCOLL, Mr T F BEATTIE, and Dr J
W GERRARD (Accident and Emergency Department,
Royal Preston Hospital, Preston PR2 4HT) write: We
share the concern expressed by Mr D W Yates and
Ms H Chambers about the number of assaults that
they see in their accident department and the strong
relation between such assaults and alcohol (4 April,
p 901). We recently reviewed the problem in this
hospital. Assaults constituted 2-5% of our workload,
alcohol was a factor in 80% of assaults, and we
estimated that the cost to our health authority in 1986
was £100 000.
Drug points
Lead poisoning in heroin addicts
Dr S MONTEFORT and colleagues (St Luke's Hospital,
Gwardamangia, Malta) write: In Malta over the
past year we have encountered several cases of lead
poisoning in heroin addicts. A 21 year old man, a
known heroin abuser, presented in December 1985
with abdominal pain, distension, and constipation.
Abdominal radiography showed severe colonic
distension, and opiate induced colonic pseudo-
obstruction was diagnosed and colonoscopic de-
compression performed. He was, however, found to
have severe sideroblastic anaemia and a blood lead
concentration of 1010 tcg/l (on absorption spectro-
photometry the 90th centile for normal subjects is
343 Ftg/l).' There was no history of occupational
exposure to lead, and a sample of heroin provided by
the patient contained 21 mg lead/g powder. The
sample also contained calcium and silicon (thought to
be due to talc) and small traces of several other metals,
including copper, zinc, iron, and chromium. Since
screening was subsequently introduced 46 episodes of
lead toxicity have been diagnosed in 22 known heroin
abusers (with up to four admissions each). There
were 19 men and three women, age range 20-33. All
patients had gastrointestinal symptoms on presenta-
tion, including abdominal pain (10%), constipation
(90%), nausea or vomiting (95%), and abdominal
distension (30%). Weakness and pallor were also
frequent (90%); one patient suffered from tremulous-
ness. All patients had anaemia, with haemoglobin
concentrations ranging from 65 g/l to 120 g/l. Lead
concentrations ranged from 506 ,ug/l to 3648 ug/l.
Anaemia was treated with blood transfusion, and
intravenous edetic acid, with or without oral penicil-
lamine, was used to lower blood lead concentrations.
The patients became asymptomatic, with oral metha-
done, and in some cases clonidine, being given for
withdrawal symptoms. Despite the knowledge that
the heroin was contaminated 30% of the patients were
readmitted within weeks with a recurrence of lead
toxicity and admitted to further heroin abuse, many
having also stopped.taking penicillamine.
In a known intravenous drug abuser the combina-
tion of anaemia and gastrointestinal symptoms should
suggest the association oflead toxicity and intravenous
heroin abuse. Lead poisoning has been reported in
addicts who injected themselves with ground up lead
and opium pills.2 In our patients, however, lead salts,
probably acetate or nitrate, were added to heroin as a
white powder to increase the selling weight. Talc may
also be used to dilute heroin, and poisoning with
non-infectious contaminants is becoming increasingly
recognised as a complication of intravenous drug
abuse.3 4
Treatment is difficult, because poor compliance
hinders attempts to reduce the total body lead stores
with oral chelating agents. In addition, awareness of
the risks of lead poisoning did not prevent many
of these drug abusers from reusing a known con-
taminated source.
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Prescribing in pregnancy: rifampicin
Dr NALIN K ASHUBODHA (Mahabuthgamuwa, Sri
Lanka) writes: Dr Richard Wise's article on prescrib-
ing antibiotics in pregnancy (3 January, p 42) is
particularly pertinent to the tropical world, where
antibiotics are often misused, overused, or underused.
Rifampicin was used in 11 pregnant patients with
leprosy (age range 19-31) in the pilot multidrug
therapy trials at Shashamene, south Ethiopia.' Nine
of the 11 were paucibacillary patients, who had been
receiving dapsone 100 mg orally daily and rifampicin
600 mg orally monthly, with supervision, for six
months. The remaining two patients, who were
multibacillary, had been receiving dapsone 100
mg daily, clofazimine (Lamprene) 100 mg daily,
rifampicin 600 mg monthly, and clofazimine 300 mg
monthly for two years.2 Most of these patients were
included in the study without our knowing that they
were pregnant. All of the patients were given strict
contraceptive advice during the test period, and a
special family planning clinic was set up for them.
When we began to suspect that they were pregnant the
first trimester was already over. At the end of the first
trimester I suggested that the patients should continue
to take rifampicin 600 mg monthly with the other
antileprotic drugs for the respective test periods. A
good history, particularly of gastrointestinal symp-
toms, fevers, and shortness of breath, and a general
physical examination with skin examination in good
daylight were mandatory. Laboratory investigations
included haemoglobin tests, differential and total
white blood cell counts, urine analysis, and liver
function tests.3
No toxic effects are encountered in non-pregnant
patients with leprosy who receive doses of rifampicin
monthly. Similarly, we found no toxic effects in
pregnant patients with leprosy who received 600 mg
rifampicin monthly.
I Ashubodha NK. Multi drug therapy trials in Shashamene. Addis
Ababa, Ethiopia: Ministry of Health, 1983.
2 World Health Organisation. Chemotherapy ofleprosy for control
programnues. WHO Tech Rep Ser 1982; No 675.
3 World Health Organisation. A guide to leprosy control. Geneva:
World Health Organisation, 1980.
Ventricular tachycardia after self poisoning
with dichloralphenazone and diazepam
Dr J A LOCKTON (Wythenshawe, Manchester) writes:
There have been several reports of ventricular
arrhythmia after self poisoning with chloral hydrate'"3
and supraventricular tachycardias in children receiv-
ing chloral hydrate after cardiac surgery.4 Arrhythmias
have not been reported with the related drug dichloral-
phenazone.
A 30 year old woman was prescribed 90 tablets of
diazepam 10 mg and 90 tablets of dichloralphenazone
650 mg by her general practitioner. She was admitted
to hospital 10 days later after taking an overdose of the
tablets. Cardiac monitoring showed multiple ectopic
beats and short, self terminating runs of ventricular
tachycardia. No treatment was required and she
recovered uneventfully. Urine toxicology on a sample
taken 12 hours after admission showed dichloral-
phenazone and its metabolites. She was readmitted
three months later, again deeply unconscious. She had
been found with an empty packet of dichloralphena-
zone tablets, having collected a further prescription
for diazepam and dichloralphenazone tablets two days
earlier. Ventricular tachycardia recurred, this time
with cardiovascular collapse. This failed to respond to
defibrillation after boluses of lignocaine 100 mg and
bretylium but reverted to sinus rhythm during a half
hour infusion of amiodarone 375 mg. Subsequently
she recovered. Clinical examination and electrocardio-
graphy during each admission showed no evidence of
underlying cardiac disease.
Ventricular tachycardia in our patient was probably
due to dichloralphenazone as this drug is metabolised
to chloral hydrate, with which ventricular tachycardia
has been described. The Leeds poison centre con-
firmed that there had been reports of ventricular
tachycardia with dichloralpenazone, although none
have been published. The mechanism is thought to be
sensitisation of the myocardium to endogenous cate-
cholamines and the treatment of choice ,1 blockade.
There have been no such reports concerning diazepam
even though it is commonly taken in cases of self
poisoning.
I thank Dr N Brookes (consultant cardiologist) for
his help in preparing this report and Dr J J Manns
(consultant general physician) for permitting me to
report this case.
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Pinpoint pupils in mianserin overdose
Dr G N FULLER and Ms JANET CLARBOUR (St
Stephen's Hospital, London SW1O 9TH) write: Pin-
point pupils in a drowsy patient who has taken an
overdose are usually associated with opiates.' We
describe a case in which these findings were due to
mianserin. A 33 year old woman was seen two hours
after taking 25-40 tablets ofmianserin 30 mgand halfa
bottie of rum. She denied taking any other drugs and
was receiving no regular medication. On examination
she was drowsy, but able to answer questions, and had
pinpoint pupils. An electrocardiogram confirmed her
tachycardia of 120 beats/min and showed no conduc-
tion defect. Naloxone 2-4 mg was administered intra-
venously with no response in either pupil size or level
of consciousness. Gastric washout was performed. Six
hours after the overdose she was alert and her pupils
were 2 mm in diameter. Twenty four hours later they
were 4 mm in diameter and reacting normally to
light and accommodation. Toxological analysis sub-
sequently confirmed that no other agents had been
taken. Two hours after overdose mianserin concen-
trations were 0 39 mg/l, desmethylrnianserin 0 07 mg/
I, and ethanol 3 00 mg/I. Therapeutic concentrations
of mianserin (plus desmethylmianserin) are 0 1 mg/Il,
and serious toxicity is associated with concentrations
aboveO 5 mg/I.
Pinpoint pupils have been reported in mianserin
overdose before, once in mianserin alone and twice in
combination with other drugs.2 In studies of normal
volunteers3 and depressed patients" mianserin pro-
duced a statistically significant reduction in pupil
diameter of 1 0-1 5 mm. The mechanism of this effect
is not clear, but at therapeutic levels it was suggested
that it was either centrally mediated or from inter-
actions with receptors other than cholinergic or adre-
nergic.5 Mianserin in overdose is a possible cause of
pinpoint pupils unresponsive to naloxone.
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